A Case of Immune-Mediated Pneumonitis Associated With Dual Nivolumab and Ipilimumab Immunotherapy Treatment
Nivolumab and ipilimumab are immunotherapy agents used in combination to treat metastatic melanoma and have proven to be efficacious. However, they have been linked to the development of immune-mediated inflammatory processes in various organ systems and tissues, including immune-mediated pneumoniti...
Gespeichert in:
| Veröffentlicht in: | Curēus (Palo Alto, CA) CA), 2023-06, Vol.15 (6), p.e40792 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 6 |
| container_start_page | e40792 |
| container_title | Curēus (Palo Alto, CA) |
| container_volume | 15 |
| creator | Al-Saghir, Tala Suleiman, Noor Goodman, Benjamin D Ferguson, Michael W Tejwani, Sheela |
| description | Nivolumab and ipilimumab are immunotherapy agents used in combination to treat metastatic melanoma and have proven to be efficacious. However, they have been linked to the development of immune-mediated inflammatory processes in various organ systems and tissues, including immune-mediated pneumonitis (IMP). This case report describes a 50-year-old female patient with metastatic melanoma who was treated with nivolumab and ipilimumab therapy and developed IMP as a complication. Despite treatment with steroids and infliximab, the patient's condition worsened, and she passed away due to respiratory compromise. This report emphasizes the potential for serious complications in patients receiving combination immunotherapy and highlights the importance of close monitoring and risk stratification, particularly in patients with underlying lung conditions. |
| doi_str_mv | 10.7759/cureus.40792 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10362781</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2844029773</sourcerecordid><originalsourceid>FETCH-LOGICAL-c267t-40a206882317fef3c66c76bbb022452fb48fee7eb93887b13fcc0d602baa9543</originalsourceid><addsrcrecordid>eNpVkUtr3DAUhUVJaUKaXddFkG2cXj3GkldhmKTtQPpYDHQpJPm6o8S2JpIVyL-vO5OGdHVfh-9cOIR8YHCp1KL55EvCki8lqIa_ISec1brSTMujV_0xOcv5DgAYKA4K3pFjoaReMIATcr-kK5uRxo6uh6GMWH3DNtgJW_pzxDLEMUwh02XO0R_Wv8K0pdfF9vR7eIx9Gayjdmzpehf6MOzHPSlOW0x290Q3Ce004Di9J28722c8e66nZPP5ZrP6Wt3--LJeLW8rz2s1VRIsh1prLpjqsBO-rr2qnXPAuVzwzkndISp0jdBaOSY676GtgTtrm4UUp-TqgN0VN2DrZ-dke7NLYbDpyUQbzP-XMWzN7_hoGIiaK81mwvkzIcWHgnkyd7Gkcf7ZcC0l8EYpMasuDiqfYs4JuxcLBuZvOuaQjtmnM8s_vn7rRfwvC_EHC9WN2g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2844029773</pqid></control><display><type>article</type><title>A Case of Immune-Mediated Pneumonitis Associated With Dual Nivolumab and Ipilimumab Immunotherapy Treatment</title><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Al-Saghir, Tala ; Suleiman, Noor ; Goodman, Benjamin D ; Ferguson, Michael W ; Tejwani, Sheela</creator><creatorcontrib>Al-Saghir, Tala ; Suleiman, Noor ; Goodman, Benjamin D ; Ferguson, Michael W ; Tejwani, Sheela</creatorcontrib><description>Nivolumab and ipilimumab are immunotherapy agents used in combination to treat metastatic melanoma and have proven to be efficacious. However, they have been linked to the development of immune-mediated inflammatory processes in various organ systems and tissues, including immune-mediated pneumonitis (IMP). This case report describes a 50-year-old female patient with metastatic melanoma who was treated with nivolumab and ipilimumab therapy and developed IMP as a complication. Despite treatment with steroids and infliximab, the patient's condition worsened, and she passed away due to respiratory compromise. This report emphasizes the potential for serious complications in patients receiving combination immunotherapy and highlights the importance of close monitoring and risk stratification, particularly in patients with underlying lung conditions.</description><identifier>ISSN: 2168-8184</identifier><identifier>EISSN: 2168-8184</identifier><identifier>DOI: 10.7759/cureus.40792</identifier><identifier>PMID: 37485100</identifier><language>eng</language><publisher>United States: Cureus Inc</publisher><subject>Case reports ; Chronic obstructive pulmonary disease ; Hospitals ; Immunotherapy ; Internal Medicine ; Lung cancer ; Lung diseases ; Melanoma ; Metastasis ; Monoclonal antibodies ; Mortality ; Oncology ; Patients ; Pleural effusion ; Pulmonology ; Quality of life ; Skin cancer ; Sleep apnea ; Steroids</subject><ispartof>Curēus (Palo Alto, CA), 2023-06, Vol.15 (6), p.e40792</ispartof><rights>Copyright © 2023, Al-Saghir et al.</rights><rights>Copyright © 2023, Al-Saghir et al. This work is published under https://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2023, Al-Saghir et al. 2023 Al-Saghir et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c267t-40a206882317fef3c66c76bbb022452fb48fee7eb93887b13fcc0d602baa9543</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362781/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362781/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37485100$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Al-Saghir, Tala</creatorcontrib><creatorcontrib>Suleiman, Noor</creatorcontrib><creatorcontrib>Goodman, Benjamin D</creatorcontrib><creatorcontrib>Ferguson, Michael W</creatorcontrib><creatorcontrib>Tejwani, Sheela</creatorcontrib><title>A Case of Immune-Mediated Pneumonitis Associated With Dual Nivolumab and Ipilimumab Immunotherapy Treatment</title><title>Curēus (Palo Alto, CA)</title><addtitle>Cureus</addtitle><description>Nivolumab and ipilimumab are immunotherapy agents used in combination to treat metastatic melanoma and have proven to be efficacious. However, they have been linked to the development of immune-mediated inflammatory processes in various organ systems and tissues, including immune-mediated pneumonitis (IMP). This case report describes a 50-year-old female patient with metastatic melanoma who was treated with nivolumab and ipilimumab therapy and developed IMP as a complication. Despite treatment with steroids and infliximab, the patient's condition worsened, and she passed away due to respiratory compromise. This report emphasizes the potential for serious complications in patients receiving combination immunotherapy and highlights the importance of close monitoring and risk stratification, particularly in patients with underlying lung conditions.</description><subject>Case reports</subject><subject>Chronic obstructive pulmonary disease</subject><subject>Hospitals</subject><subject>Immunotherapy</subject><subject>Internal Medicine</subject><subject>Lung cancer</subject><subject>Lung diseases</subject><subject>Melanoma</subject><subject>Metastasis</subject><subject>Monoclonal antibodies</subject><subject>Mortality</subject><subject>Oncology</subject><subject>Patients</subject><subject>Pleural effusion</subject><subject>Pulmonology</subject><subject>Quality of life</subject><subject>Skin cancer</subject><subject>Sleep apnea</subject><subject>Steroids</subject><issn>2168-8184</issn><issn>2168-8184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpVkUtr3DAUhUVJaUKaXddFkG2cXj3GkldhmKTtQPpYDHQpJPm6o8S2JpIVyL-vO5OGdHVfh-9cOIR8YHCp1KL55EvCki8lqIa_ISec1brSTMujV_0xOcv5DgAYKA4K3pFjoaReMIATcr-kK5uRxo6uh6GMWH3DNtgJW_pzxDLEMUwh02XO0R_Wv8K0pdfF9vR7eIx9Gayjdmzpehf6MOzHPSlOW0x290Q3Ce004Di9J28722c8e66nZPP5ZrP6Wt3--LJeLW8rz2s1VRIsh1prLpjqsBO-rr2qnXPAuVzwzkndISp0jdBaOSY676GtgTtrm4UUp-TqgN0VN2DrZ-dke7NLYbDpyUQbzP-XMWzN7_hoGIiaK81mwvkzIcWHgnkyd7Gkcf7ZcC0l8EYpMasuDiqfYs4JuxcLBuZvOuaQjtmnM8s_vn7rRfwvC_EHC9WN2g</recordid><startdate>20230622</startdate><enddate>20230622</enddate><creator>Al-Saghir, Tala</creator><creator>Suleiman, Noor</creator><creator>Goodman, Benjamin D</creator><creator>Ferguson, Michael W</creator><creator>Tejwani, Sheela</creator><general>Cureus Inc</general><general>Cureus</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>5PM</scope></search><sort><creationdate>20230622</creationdate><title>A Case of Immune-Mediated Pneumonitis Associated With Dual Nivolumab and Ipilimumab Immunotherapy Treatment</title><author>Al-Saghir, Tala ; Suleiman, Noor ; Goodman, Benjamin D ; Ferguson, Michael W ; Tejwani, Sheela</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c267t-40a206882317fef3c66c76bbb022452fb48fee7eb93887b13fcc0d602baa9543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Case reports</topic><topic>Chronic obstructive pulmonary disease</topic><topic>Hospitals</topic><topic>Immunotherapy</topic><topic>Internal Medicine</topic><topic>Lung cancer</topic><topic>Lung diseases</topic><topic>Melanoma</topic><topic>Metastasis</topic><topic>Monoclonal antibodies</topic><topic>Mortality</topic><topic>Oncology</topic><topic>Patients</topic><topic>Pleural effusion</topic><topic>Pulmonology</topic><topic>Quality of life</topic><topic>Skin cancer</topic><topic>Sleep apnea</topic><topic>Steroids</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Al-Saghir, Tala</creatorcontrib><creatorcontrib>Suleiman, Noor</creatorcontrib><creatorcontrib>Goodman, Benjamin D</creatorcontrib><creatorcontrib>Ferguson, Michael W</creatorcontrib><creatorcontrib>Tejwani, Sheela</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Curēus (Palo Alto, CA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Al-Saghir, Tala</au><au>Suleiman, Noor</au><au>Goodman, Benjamin D</au><au>Ferguson, Michael W</au><au>Tejwani, Sheela</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Case of Immune-Mediated Pneumonitis Associated With Dual Nivolumab and Ipilimumab Immunotherapy Treatment</atitle><jtitle>Curēus (Palo Alto, CA)</jtitle><addtitle>Cureus</addtitle><date>2023-06-22</date><risdate>2023</risdate><volume>15</volume><issue>6</issue><spage>e40792</spage><pages>e40792-</pages><issn>2168-8184</issn><eissn>2168-8184</eissn><abstract>Nivolumab and ipilimumab are immunotherapy agents used in combination to treat metastatic melanoma and have proven to be efficacious. However, they have been linked to the development of immune-mediated inflammatory processes in various organ systems and tissues, including immune-mediated pneumonitis (IMP). This case report describes a 50-year-old female patient with metastatic melanoma who was treated with nivolumab and ipilimumab therapy and developed IMP as a complication. Despite treatment with steroids and infliximab, the patient's condition worsened, and she passed away due to respiratory compromise. This report emphasizes the potential for serious complications in patients receiving combination immunotherapy and highlights the importance of close monitoring and risk stratification, particularly in patients with underlying lung conditions.</abstract><cop>United States</cop><pub>Cureus Inc</pub><pmid>37485100</pmid><doi>10.7759/cureus.40792</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2168-8184 |
| ispartof | Curēus (Palo Alto, CA), 2023-06, Vol.15 (6), p.e40792 |
| issn | 2168-8184 2168-8184 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10362781 |
| source | PubMed Central; PubMed Central Open Access |
| subjects | Case reports Chronic obstructive pulmonary disease Hospitals Immunotherapy Internal Medicine Lung cancer Lung diseases Melanoma Metastasis Monoclonal antibodies Mortality Oncology Patients Pleural effusion Pulmonology Quality of life Skin cancer Sleep apnea Steroids |
| title | A Case of Immune-Mediated Pneumonitis Associated With Dual Nivolumab and Ipilimumab Immunotherapy Treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T10%3A15%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Case%20of%20Immune-Mediated%20Pneumonitis%20Associated%20With%20Dual%20Nivolumab%20and%20Ipilimumab%20Immunotherapy%20Treatment&rft.jtitle=Cur%C4%93us%20(Palo%20Alto,%20CA)&rft.au=Al-Saghir,%20Tala&rft.date=2023-06-22&rft.volume=15&rft.issue=6&rft.spage=e40792&rft.pages=e40792-&rft.issn=2168-8184&rft.eissn=2168-8184&rft_id=info:doi/10.7759/cureus.40792&rft_dat=%3Cproquest_pubme%3E2844029773%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2844029773&rft_id=info:pmid/37485100&rfr_iscdi=true |